142 related articles for article (PubMed ID: 36925195)
1. The Role of ESRP1 in the Regulation of PHGDH in Estrogen Receptor-Positive Breast Cancer.
Gökmen-Polar Y; Gu Y; Polar A; Gu X; Badve SS
Lab Invest; 2023 Mar; 103(3):100002. PubMed ID: 36925195
[TBL] [Abstract][Full Text] [Related]
2. Splicing factor
Gökmen-Polar Y; Neelamraju Y; Goswami CP; Gu Y; Gu X; Nallamothu G; Vieth E; Janga SC; Ryan M; Badve SS
EMBO Rep; 2019 Feb; 20(2):. PubMed ID: 30665944
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells.
Petri BJ; Piell KM; Wilt AE; Howser AD; Winkler L; Whitworth MR; Valdes BL; Lehman NL; Clem BF; Klinge CM
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37650685
[TBL] [Abstract][Full Text] [Related]
4. A Regulatory Axis between Epithelial Splicing Regulatory Proteins and Estrogen Receptor α Modulates the Alternative Transcriptome of Luminal Breast Cancer.
Elhasnaoui J; Ferrero G; Miano V; Franchitti L; Tarulli I; Coscujuela Tarrero L; Cutrupi S; De Bortoli M
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887187
[TBL] [Abstract][Full Text] [Related]
5. Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer.
Gökmen-Polar Y; Neelamraju Y; Goswami CP; Gu X; Nallamothu G; Janga SC; Badve S
Mod Pathol; 2015 May; 28(5):677-85. PubMed ID: 25431237
[TBL] [Abstract][Full Text] [Related]
6. Serine synthesis influences tamoxifen response in ER+ human breast carcinoma.
Metcalf S; Petri BJ; Kruer T; Green B; Dougherty S; Wittliff JL; Klinge CM; Clem BF
Endocr Relat Cancer; 2021 Jan; 28(1):27-37. PubMed ID: 33112838
[TBL] [Abstract][Full Text] [Related]
7. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
[TBL] [Abstract][Full Text] [Related]
8. The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer.
Calaluce R; Gubin MM; Davis JW; Magee JD; Chen J; Kuwano Y; Gorospe M; Atasoy U
BMC Cancer; 2010 Apr; 10():126. PubMed ID: 20370918
[TBL] [Abstract][Full Text] [Related]
9. Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth.
Chen J; Chung F; Yang G; Pu M; Gao H; Jiang W; Yin H; Capka V; Kasibhatla S; Laffitte B; Jaeger S; Pagliarini R; Chen Y; Zhou W
Oncotarget; 2013 Dec; 4(12):2502-11. PubMed ID: 24318446
[TBL] [Abstract][Full Text] [Related]
10. Epithelial Splicing Regulatory Protein 1 Is Overexpressed in Breast Cancer and Predicts Poor Prognosis for Breast Cancer Patients.
Liu X; Wang Q; Song S; Feng M; Wang X; Li L; Liu Y; Shi C
Med Sci Monit; 2021 Jul; 27():e931102. PubMed ID: 34262011
[TBL] [Abstract][Full Text] [Related]
11. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
12. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer.
Possemato R; Marks KM; Shaul YD; Pacold ME; Kim D; Birsoy K; Sethumadhavan S; Woo HK; Jang HG; Jha AK; Chen WW; Barrett FG; Stransky N; Tsun ZY; Cowley GS; Barretina J; Kalaany NY; Hsu PP; Ottina K; Chan AM; Yuan B; Garraway LA; Root DE; Mino-Kenudson M; Brachtel EF; Driggers EM; Sabatini DM
Nature; 2011 Aug; 476(7360):346-50. PubMed ID: 21760589
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.
Chandrika M; Chua PJ; Muniasamy U; Huang RYJ; Thike AA; Ng CT; Tan PH; Yip GW; Bay BH
Breast Cancer Res Treat; 2021 Apr; 186(3):655-665. PubMed ID: 33625616
[TBL] [Abstract][Full Text] [Related]
14. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.
Hostetter C; Licata LA; Witkiewicz A; Costantino CL; Yeo CJ; Brody JR; Keen JC
Cancer Biol Ther; 2008 Sep; 7(9):1496-506. PubMed ID: 18769129
[TBL] [Abstract][Full Text] [Related]
16. Acetylation Stabilizes Phosphoglycerate Dehydrogenase by Disrupting the Interaction of E3 Ligase RNF5 to Promote Breast Tumorigenesis.
Wang C; Wan X; Yu T; Huang Z; Shen C; Qi Q; Xiang S; Chen X; Arbely E; Ling ZQ; Liu CY; Yu W
Cell Rep; 2020 Aug; 32(6):108021. PubMed ID: 32783943
[TBL] [Abstract][Full Text] [Related]
17. Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
Ma X; Li B; Liu J; Fu Y; Luo Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):66. PubMed ID: 30744688
[TBL] [Abstract][Full Text] [Related]
18. Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells.
Sharif T; Martell E; Dai C; Ghassemi-Rad MS; Lee K; Singh SK; Weaver ICG; Gujar S
Cell Death Dis; 2018 Sep; 9(10):990. PubMed ID: 30250195
[TBL] [Abstract][Full Text] [Related]
19. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
